Introduction
============

Genetic factors are responsible for a large (40--80%) proportion of individual variability in measurements of blood pressure (BP) and cerebral integrity (Kochunov et al., [@B23], [@B21]; Winkler et al., [@B46]). Elevated BP shares genetic risk factors with genetic risk factors for decline in cerebral integrity in both hypertensive (Turner et al., [@B44]) and normally aging populations (DeStefano et al., [@B10]; Kochunov et al., [@B22], [@B24]). Some these risk factors were localized to a region on the q-arm of chromosome one (1q24; Turner et al., [@B44]; Kochunov et al., [@B22]). This region was also previously identified as harboring risk genes for development of cardiovascular disorders (Blann et al., [@B5]; Zee et al., [@B49]; Rutherford et al., [@B38]) and essential hypertension (Duggirala et al., [@B12]; Chang et al., [@B8]; Goring et al., [@B16]). Five genes within this region, including a constellation of *selectin* (*SELP*, *SELL*, and *SELE*) genes, *ATP1B1* and the coagulation factor V (*F5*) genes, were confirmed to be involved in determining individual susceptibility for essential hypertension (Kochunov et al., [@B23], [@B21]). Previously, we hypothesized that *P-selectin* (*SELP*) gene was a likely contributor to the variations in BP and brain atrophy BP (Kochunov et al., [@B22], [@B24]). Elevated platelet *P-selectin* expression level is a marker of endothelial dysfunction (Nomura et al., [@B34]) and is positively correlated with systolic BP, pulse pressure, and diagnosis of hypertension (Lee et al., [@B29]; Reiner et al., [@B37]; Nomura et al., [@B34]). Common *SELP* sequence variants also explain a significant proportion of individual variability in the soluble P-selectin protein levels, even after correcting for environmental factors such as smoking (Lee et al., [@B29]; Reiner et al., [@B37]). Furthermore, *SELP* 1087A/G polymorphism is a predictor of poorer neurocognitive functioning in hypertensive elderly (Gunstad et al., [@B17]). Here, we aimed to test the hypothesis that elevated *P-selectin* expression levels predict declining brain integrity. To this end, we employed genetic correlations with quantitative mRNA expressions measured in large, extended pedigree (Blangero et al., [@B4]). This approach has strategic benefits such as the increased power to study causal genes and increased power to detect the effects of rare functional variants, over the more common strategy that has focused upon collections of unrelated individuals (Blangero et al., [@B4]).

We performed these analyses using leukocyte-based mRNA expression measurements for 12 genes the 1q24 region and three magnetic resonance imaging (MRI)-derived measurements of cerebral integrity in a well-characterized population of normally aging, community-dwelling Mexican-Americans from large extended families (Mitchell et al., [@B33]). Gene expression measurements were performed on the lymphocytes exacted from blood samples collected 16 year prior to collection of imaging data; hence, giving a prospective element to the brain measures. Previous analyses in this population established a positive correlation between elevated expression levels for *P-selectin* and arterial hypertension (Goring et al., [@B16]). Additional analyses demonstrated a genetic relationship among BP measurements and two MRI-derived measurements of cerebral white matter (WM) integrity (Kochunov et al., [@B22], [@B24]). Specifically, elevated arterial pulse pressure and systolic BP corresponded to lower fractional anisotropy (FA) of cerebral WM values (Kochunov et al., [@B24]). Elevated arterial pulse pressure and systolic BP also corresponded to the increased volumes of subcortical and ependymal hyperintensive WM (HWM) regions (Kochunov et al., [@B22]), which is a classical marker of focal WM atrophy (Fazekas et al., [@B14]). Here, we propose to test the next logical hypothesis that there should be a significant degree of shared genetic variance between cerebral atrophy and gene expression level of *P-selectin* and/or others genes located at the 1q24 QTL region. In addition to two previously used measurements of WM atrophy, we obtained whole-brain and regional measurements of cortical gray matter (GM) thickness to estimate intersubject differences in the integrity of cortical GM (Huttenlocher and Dabholkar, [@B20]).

Materials and Methods
=====================

Subjects
--------

Three hundred sixty-nine (219 females) active participants in the San Antonio Family Heart Study (SAFHS; Mitchell et al., [@B33]), for whom gene expression and brain imaging data were available. They are Mexican-Americans from large extended families selected randomly from the community. Subjects ranged from 28 to 85 years of age (47.1 ± 12.7 years) and were members of 47 families (9.3 ± 8.2 individuals/family; range 2--38). Subjects' demographic and health information is detailed in Table [1](#T1){ref-type="table"}. Four hundred forty-eight SAFHS subjects, for whom transcript data were available agreed to participate in the imaging study. Forty-six subjects were excluded from the imaging for: MRI contraindications such as claustrophobia or presents of metal in their bodies (*N* = 35), history of neurological illnesses, such as multiple sclerosis (*N* = 6), or stroke, transient ischemic attack or other major neurological event (*N* = 5). Complete MRI data was not collected for 33 subjects because a subject was unable to complete the MRI session (*N* = 26), scanner malfunction (*N* = 4), and other reasons (*N* = 3). All subjects provided written informed consent on forms approved by the Institutional Review Board of the University of Texas Health Science Center at San Antonio (UTHSCSA) and Yale University.

###### 

**Thirteen measurements of gene transcriptions were available for 12 genes located on chromos 1q24 between markers rs137915045 and rs111909575**.

  Target ID\*     Accession number\*   Gene ID\*\*   Protein name                                                     Location\*\*   Length\*\*   Heritability (*p*)
  --------------- -------------------- ------------- ---------------------------------------------------------------- -------------- ------------ --------------------
  GI_37595556-S   NM_001677.2          *ATP1B1*      Sodium/potassium-transporting ATPase subunit beta-1              169,075,947    26,014       0.315 (10^−10^)
  GI_37574613-A   NM_197972.1          *NME7*        Nucleoside diphosphate kinase 7                                  169,101,769    235,418      0.231 (10^−6^)
  GI_37622354-S   NM_003666.2          *BLZF1*       Basic leucine zipper nuclear factor 1                            169,337,194    28,589       0.25 (10^−10^)
  GI_27734718-S   NM_006996.1          *SLC19A2*     Thiamine transporter 1                                           169,433,147    22,062       0.04 (10^−3^)
  GI_10518500-S   NM_000130.2          *F5*          Coagulation factor V                                             169,481,192    74,578       0.35 (10^−10^)
  GI_6031196-S    NM_003005.2          *SELP*        P-selectin                                                       169,558,087    41,291       0.34 (10^−10^)
  GI_5713320-S    NM_000655.2          *SELL*        L-selectin                                                       169,659,806    21,038       0.27 (10^−10^)
  GI_15553096-S   NM_033418.1          *C1orf156*    Histidine protein methyltransferase 1 homolog                    169,761,670    2362         0.44 (10^−10^)
  GI_40254930-S   NM_018186.2          *C1orf112*    Uncharacterized protein C1orf112                                 169,764,550    57,680       0.20 (10^−6^)
  GI_27363466-A   NM_020423.4          *SCYL3*       Protein-associating with the carboxyl-terminal domain of ezrin   169,821,804    41,273       0.40 (10^−10^)
  GI_41281932-I   NM_181093.1          *SCYL3*       Protein-associating with the carboxyl-terminal domain of ezrin   169,821,804    41,273       0.12 (10^−3^)
  GI_18105053-S   NM_014970.2          *KIFAP3*      Kinesin-associated protein 3                                     169,890,470    153,410      0.32 (10^−10^)
  GI_22748638-S   NM_152281.1          *GORAB*       RAB6-interacting golgin                                          170,501,263    21,712       0.25 (10^−7^)

*\*Illumina ID. \*\*According to GRCh37.p2 primary reference assembly*.

### MR imaging and data processing

Imaging data were collected using a Siemens 3 T Trio scanner located at the Research Imaging Institute, UTHSCSA. The details of imaging protocol and data collection are described elsewhere (Kochunov et al., [@B25]). In short, this study used a multimodal MRI protocol specifically optimized for measurements of GM thickness, FA values, and volume of HWM lesions.

The protocol for measurements of GM thickness was designed to collect data capable of resolving the cortical ribbon across the cerebral cortex using an isotropic spatial resolution of 0.8 mm (voxel volume = 0.5 mm^3^). T1-weighted contrast was achieved using a magnetization prepared sequence with an adiabatic inversion contrast-forming pulse (scan parameters: TE/TR/TI = 3.04/2100/785 ms, flip angle = 11°). A retrospective motion correction technique (Kochunov et al., [@B25]) was used to reduce artifacts related to subject motion. Whole-brain average and regional measurements of cortical thickness were performed using a freely available BrainVisa software (Kochunov et al., [@B27]; Figure [1](#F1){ref-type="fig"})[^1^](#fn1){ref-type="fn"}. This tool uses a "normal-average" algorithm that has been reported to be a good compromise between accuracy and performance (Lerch and Evans, [@B30]). The GM thickness is measured as the Euclidean distance from an inner mesh vertex to the outer mesh along the direction normal to the inner mesh polygon. The measurement is repeated, inward, along the direction normal the outer mesh and the two distances are averaged (Kochunov et al., [@B28]). The consistency of the distance measurements is ensured by verifying that the line connecting the two surfaces does not intersect other polygons, inner or outer, along the way. GM thickness measurements were averaged for individual cortical areas for both hemispheres; the whole-brain GM thickness measurement was obtained by averaging all gyral GM thickness measurements as described elsewhere (Wakana et al., [@B45]).

![**T1-w image processing pipelines**. A T1-w image is skull-stripped, globally spatially normalized, and RF inhomogeneity corrected **(A)**. Next, cerebral hemispheres and cerebellum and identified and tissue classified **(B)**; cortical surfaces for GM and WM are calculated **(C,D)** and homotopic erosion operation and crevasse detector are used to reconstruct sulcal surface as the medial surface of the two opposing gyral banks **(E)**. Sulcal identification pipeline uses a congregation of 500 artificial neural network-based pattern classifiers to identify **(F)** sulcal landmarks and to perform gyral segmentation of the cortex **(G)**. GM thickness was calculate as the distance between the pial **(C)** and GM/WM interface surfaces **(H)**. **(I)** Average GM thickness was calculated 14 primary cortical gyri.](fgene-03-00065-g001){#F1}

Diffusion tensor data were collected using a single-shot, echo-planar, single refocusing spin-echo, T2-weighted sequence with a spatial resolution of 1.7 mm × 1.7 mm × 3.0 mm. The sequence parameters were: TE/TR = 87/8000 ms, FOV = 200 mm, axial slice orientation with 50 slices, and no gaps, 55 isotropically distributed diffusion weighted directions, two diffusion weighting values (*b* = 0 and 700 s/mm^2^) and three *b* = 0 images. Details for the choice of DTI parameters and processing of DTI scans, including extracting whole-brain and regional FA values, are discussed elsewhere (Kochunov et al., [@B25]). In short, the tract-based spatial statistics (TBSS) software (Kochunov et al., [@B25]) was used for multi-subject analysis of FA images. Whole-brain average FA values were calculated by averaging values for the entire WM skeleton. Average FA values were calculated for nine major WM tracts (Figure [2](#F2){ref-type="fig"}) as described elsewhere (Kochunov et al., [@B21], [@B26]). Briefly, the population-based, 3D, DTI cerebral WM tract atlas developed at the John Hopkins University (JHU) and distributed as part of the FSL software package (Wakana et al., [@B45]) was used to calculate population average diffusion parameter values along the nine major WM tracts (Figure [2](#F2){ref-type="fig"}). The JHU atlas was non-linearly aligned and labels for individual tracts were transferred to the subjects' brains using nearest-neighbor interpolation. Per-tract average values were calculated by averaging the values along the tracts for both hemispheres. The overall average FA values were calculated by averaging values for the entire WM skeleton.

![**Skeletonized, average FA values are shown on the population average FA image**. WM tract labels for nine major tracts are taken from the Johns Hopkins DTI WM atlas. The average FA values were calculated for the following tracts: corona radiata (CR), superior longitudinal fasciculus (SLF), cingulate, external capsule (EC), internal capsule (IC), fronto-occipital (FO), and the genu, body, and splenium of corpus callosum. The population-wise average FA values are color coded on the skeleton of the tract. The location of the axial slices (the *Z*-coordinate) is provided in the Talairach reference frame. The three segment of Corpus Callosum are shown on the mid-sagittal slice (Talairach *X* = 0).](fgene-03-00065-g002){#F2}

Hyperintensive WM lesion data were collected using a 3D, T2-weighted imaging using a high-resolution (isotropic 1 mm), turbo-spin-echo fluid attenuated inversion recovery (FLAIR) sequence with the following parameters: TR/TE/TI/Flip angle/ETL = 5 s/353 ms/1.8 s/180°/221. FLAIR images were preprocessed by removal of non-brain tissue, registration to the Talairach frame and correction for RF inhomogeneity. HWM regions were manually delineated in 3D-space using an in-house software[^2^](#fn2){ref-type="fn"} by an experienced neuroanatomist with high (*r*^2^ \> 0.9) test--retest reproducibility. HWM regions were coded as ependymal regions, contiguous with CSF structures, and subcortical in accordance with a technique described in (Henry Feugeas et al., [@B18]). The WB-HWM volume and the volumes of subcortical and ependymal HWM were measured for each subject.

In addition to whole-brain average measurements, regional GM thickness, FA values, and HWM volumes was calculated for 14 cortical areas, 10 major WM tracts and subcortical and ependymal (periventricular) white, respective, using the parecelation method described elsewhere (Kochunov et al., [@B25]).

Gene expression measurements
----------------------------

Thirteen gene expression transcripts were analyzed for 12 genes located in a 2-Mb region of chromosome 1, between markers rs137915045 and rs111909575 (Turner et al., [@B44]; Chang et al., [@B8]; Rutherford et al., [@B38]; Figure [3](#F3){ref-type="fig"}; Table [1](#T1){ref-type="table"}). Gene expression measures were derived from lymphocytes collected 16.6 ± 2.1 years prior to collection of imaging data. The details of gene expression measurements are described by Goring et al. ([@B16]). In short, lymphocyte were obtained from blood samples collected in the morning after an overnight fast. Lymphocytes were isolated from a 10-ml sample using Histopaque (Sigma Chemical Co.), following the suggested protocol of the manufacturer. The isolated and washed lymphocytes were frozen and stored at −80°C overnight and then transferred into liquid nitrogen tanks. Total RNA was isolated from lymphocyte samples using a modified procedure of the QIAGEN RNeasy 96 protocol for isolating total RNA from animal cells using spin technology (QIAGEN, Inc.). Its integrity was verified and anti-sense RNA was synthesized, amplified, and purified. Hybridization of anti-sense RNA was carried out using Illumina's BeadChip 6 × 2 protocol. Total isolated RNA was hybridized to Illumina Sentrix Human Whole Genome (WG-6) Series 1 BeadChips as previously described (Goring et al., [@B16]). These BeadChips simultaneously probes ∼48,000 transcripts, representing more than 25,000 annotated human genes. Processing of the sample was performed in a single batch, thereby eliminating the batch effect. Expression levels were *z*-normalized to make the expression phenotypes comparable among individuals and across transcripts (Goring et al., [@B16]). Finally, each transcript's residual expression scores were normalized by using an inverse Gaussian transformation across individuals to ensure normality (Goring et al., [@B16]).

![**Genes located under the QTL flanked rs137915045 and rs111909575**. Results (−log 10 of the *p*-value) of the correlation analysis for expression levels for the genes located under the linkage peak are plotted along the *x*-axis (bottom). The solid line corresponds to the significant evidence value of *p* = 4 × 10^−3^. The green line corresponds to the suggestive evidence value of *p* = 0.05.](fgene-03-00065-g003){#F3}

Statistical genetic analyses
----------------------------

Variance components methods, as implemented in the Sequential Oligogenic Linkage Analysis Routines (SOLAR) software package[^3^](#fn3){ref-type="fn"} (Almasy and Blangero, [@B1]), were used to estimate the degree of shared genetic variability between gene expression measurements and indexes of cerebral integrity. Briefly, the covariance matrix Ω for related individuals is given by Eq. [1](#E1){ref-type="disp-formula"}
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where $\sigma_{\text{g}}^{2}$ is the genetic variance due to residual additive genetic factors, $\sigma_{\text{e}}^{2}$ is the variance due to individual-specific environmental effects, and *I* is an identity matrix. Φ is the kinship matrix that is assembled based on the family relationships and confirmed with molecular parent-offspring genetic testing. This matrix summarizes the genetic relationships among all individuals. For additional explanation of the variance components approach using in SOLAR (see Almasy and Blangero, [@B1]; Blangero et al., [@B3]). Heritability (*h*^2^), the portion of the total phenotypic variance $\left( \sigma_{\text{P}}^{\text{2}} \right)$ that is accounted for by additive genetic variance $\left( \sigma_{\text{g}}^{2} \right),$ is assessed by contrasting the observed phenotypic covariance matrix with the covariance matrix predicted by kinship (Eq. [2](#E2){ref-type="disp-formula"}).
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Bivariate genetic analysis calculates the magnitude and significance of phenotypic correlation coefficient (ρ~P~), and the proportion of variability due to shared genetic (ρ~G~) and environmental (ρ~E~) effects. The overall phenotypic correlation (ρ~P~) between two traits A and B (Eq. [3](#E3){ref-type="disp-formula"}) can be expressed using the correlation due to shared additive genetic effects (ρ~G~) and the residual correlation (ρ~E~) due to shared environmental effects.
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Where, $h_{\text{A}}^{2}$ and $h_{\text{B}}^{2}$ denote the additive genetic heritability for each of the traits, i.e., the proportion of the total phenotypic variance that is explained by additive genetic factors. If the genetic correlation coefficient (ρ~G~) is significantly different from zero, then the significant portion of the variance in two traits are considered to be influenced by shared genetic factors (Almasy et al., [@B2]). All genetic analyses were conducted with age, sex, age~\*~sex, age^2^, and age^2^~\*~sex included as covariates. The health screening data as shown in Table [2](#T2){ref-type="table"}, were not used as covariates because of the loss of statistical power to detect genetic effects due to potential overlap in risk factors. Including covariates that potentially share both genetic and environmental variance may cause distortion of findings in unknown ways. Tests for *P-selectin* transcripts and cerebral integrity measures were considered statistically significant at *p* \< 0.05 based on the *a priori* hypothesis. Tests for correlations with the other 12 transcripts were exploratory and only the Bonferroni corrected *p* values were considered significant. Significance of the bivariate genetic and environmental correlation analysis was based on *p* \< 0.05.

###### 

**Subjects' demographic and health information including obesity (body mass index \>30), the number of subjects with hypercholesterolemia (total cholesterol levels \>200 mg/dL) and hyperlipidemia (blood lipids \>150 mg/dL), the number of subjects diagnosed with coronary heart disorder, diabetes, hypertension, the number of subjects taking antihypertensive medications, the number of subjects with alcohol dependence (AD), and the number of subject with a lifetime major depression (MD) episode**.

  Age         *N* subjects (M/F)   *N*^obese^   *N*~hyper-cholesterolemia~   *N*~hyper-lipidemia~   *N*~heart\ disorder~   *N*~diabetes~   *N*~hypertension~   *N*~anti-hypertensive\ meds~   *N*~AD~   *N*~MD~
  ----------- -------------------- ------------ ---------------------------- ---------------------- ---------------------- --------------- ------------------- ------------------------------ --------- ----------
  28--30      19 (9/10)            10           1                            0                      0                      0               1                   0                              2         3
  31--40      117 (56/61)          32           8                            3                      0                      3               18                  3                              8         18
  41--50      92 (30/62)           32           22                           6                      2                      19              16                  8                              7         27
  51--60      68 (22/46)           26           23                           4                      4                      24              15                  10                             2         24
  61--70      54 (22/32)           16           27                           10                     7                      32              18                  10                             2         9
  71--85      19 (8/11)            6            10                           3                      3                      12              7                   5                              0         5
  Total (%)   369 (40/60%)         122 (33%)    91 (25%)                     26 (7%)                16 (4%)                90 (24%)        75 (20%)            36 (10%)                       21 (6%)   86 (23%)

Results
=======

Genetic analyses reported statistically significant phenotypic correlation coefficients (ρ~P~) between mRNA expressions for *P*-*selectin* gene and all three measurements of cerebral integrity (Table [3](#T3){ref-type="table"}). A statistically significant correlation (ρ~P~) was also observed between *L*-*selectin* and FA values (*p* ≤ 0.004; Figure [3](#F3){ref-type="fig"}; Table [3](#T3){ref-type="table"}). No significant correlations were observed for any other transcripts in this region (Figure [3](#F3){ref-type="fig"}). A significant genetic correlation (*p* ≤ 0.05) was only observed between *P*-*selectin* expression levels and GM thickness and FA values (Table [2](#T2){ref-type="table"}). A significant environmental correlation (ρ~E~;)(*p* ≤ 0.05) was observed between expression levels for *L-selectin* and GM thickness and FA values.

###### 

**Results of the bivariate genetic correlation analysis included phenotypic (ρ~P~), genetic (ρ~G~), and environmental (ρ~E~) correlation coefficients and their significance (in parenthesis)**.

  Target ID                        Gene ID   Trait          ρ~P~ (*p*)         ρ~G~ (*p*)     ρ~E~ (*p*)
  -------------------------------- --------- -------------- ------------------ -------------- --------------
  **SIGNIFICANT AT *P ≤ 0.004***                                                              
  GI_6031196-S                     *SELP*    GM thickness   −0.21 (10^−4^)     −0.68 (0.04)   −0.10 (0.65)
  GI_6031196-S                     *SELP*    FA             −0.19 (4·10^−4^)   −0.50 (0.04)   −0.05 (0.90)
  GI_5713320-S                     *SELL*    FA             0.18 (3·10^−4^)    0.01 (0.95)    0.27 (0.03)
  **SIGNIFICANT AT *P ≤ 0.05***                                                               
  GI_5713320-S                     *SELL*    HWM volume     −0.12 (0.02)       0.02 (1)       −0.25 (0.06)
  GI_5713320-S                     *SELL*    GM thickness   0.11 (0.04)        0.05 (0.95)    0.24 (0.04)
  GI_6031196-S                     *SELP*    HWM volume     0.12 (0.03)        0.19 (0.20)    0.21 (0.21)

Phenotypic correlation coefficients between *P-selectin* expression and all regional GM thickness and FA measurements were significant (*p* ≤ 0.05) with exception of Sagittal Striatum (Table [4](#T4){ref-type="table"}). The sign of phenotypic correlations indicated that higher *P-selectin* expressions were associated reduced GM thickness and FA throughout the brain. Phenotypic correlation coefficients were significant between *L-selectin* expression and six regional GM thickness and for all regional FA measurements, with exception of Splenium of Corpus Callosum (Table [4](#T4){ref-type="table"}). These correlation coefficients were positive and driven by shared environmental factors (Table [4](#T4){ref-type="table"}). The correlation coefficient for the *L-selectin* expressions and subcortical HWM volumes was significant (*p* = 0.01), negative and driven by shared environmental factors (ρ~E~ = −0.25; *p* = 0.05).

###### 

**Results of the bivariate genetic correlation analysis for regional measurement of cerebral integrity**.

                                                    GI_6031196-S (*SELP*)                        GI_5713320-S (*SELL*)
  ------------------------------------------------- -------------------------------------------- ------------------------------------------
  **REGIONAL CORTICAL GM THICKNESS**                                                             
  Sup. frontal gyrus                                −0.19 (10^−3^); −0.55 (0.19); −0.09 (0.47)   0.12 (0.02); 0.69 (0.25); 0.26 (0.01)
  Interm. frontal gyrus                             −0.16 (0.003); −0.55 (0.17); −0.05 (0.65)    0.10 (0.07); 0.74 (0.19); 0.25 (0.02)
  Inf. frontal gyrus                                −0.17 (10^−3^); −0.56 (0.17); −0.07 (0.54)   0.09 (0.09); 0.68 (0.23); 0.23 (0.03)
  Pre-central gyrus                                 −0.18 (10^−3^); −0.56 (0.07); −0.03 (0.80)   0.09 (0.10); 0.60 (0.16); 0.27 (0.01)
  Orbitofrontal cortex                              −0.17 (0.002); −0.44 (0.22); −0.08 (0.50)    0.10 (0.05); 0.85 (0.12); 0.26 (0.01)
  Post-central gyrus                                −0.18 (10^−4^); −0.59 (0.05); −0.05 (0.70)   0.07 (0.22); 0.40 (0.33); 0.20 (0.09)
  Superior parietal lobule                          −0.15 (0.004); −0.43 (0.19); −0.04 (0.75)    0.10 (0.05); 0.14 (0.73); 0.17 (0.13)
  Inferior parietal lobule                          −0.18 (10^−3^); −0.46 (0.17); −0.08 (0.51)   0.09 (0.08); 0.18 (0.68); 0.16 (0.15)
  S. temporal gyrus                                 −0.20 (10^−3^); −0.47 (0.11); −0.08 (0.55)   0.08 (0.12); 0.39 (0.34); 0.21 (0.06)
  Inf. and interm. temporal gyrus                   −0.19 (10^−3^); −0.43 (0.16); −0.09 (0.47)   0.10 (0.05); 0.27 (0.49); 0.21 (0.07)
  Fusiform gyrus                                    −0.17 (0.002); −0.35 (0.22); −0.08 (0.52)    0.07 (0.19); 0.58 (0.13); 0.24 (0.03)
  Lateral occipital cortex                          −0.16 (0.003); −0.40 (0.17); −0.04 (0.75)    0.10 (0.05); 0.25 (0.48); 0.21 (0.07)
  Medial occipital cortex                           −0.19 (10^−3^); −0.49 (0.12); −0.07 (0.62)   0.10 (0.06); −30 (0.48); 0.23 (0.05)
  Cingulate gyrus                                   −0.15 (0.005); −0.56 (0.16); −0.04 (0.76)    0.12 (0.02); 0.51 (0.36); 0.26 (0.02)
  **REGIONAL FA**                                                                                
  Genu of corpus callosum                           −0.18 (0.002); −0.34 (0.09); 0.01 (0.96)     0.22 (10^−5^); 0.04 (0.90); 0.40 (0.01)
  Body of corpus callosum                           −0.18 (10^−3^); −0.48 (0.03); 0.06 (0.69)    0.18 (10^−4^); −0.11 (0.70); 0.34 (0.01)
  Splenium of corpus callosum                       −0.12 (0.03); −0.43 (0.07); 0.09 (0.56)      0.08 (0.13); 0.50 (0.29); 0.37 (0.01)
  Cingulum                                          −0.11 (0.03); −0.14 (0.62); −0.09 (0.56)     0.12 (0.02); 0.12 (0.71); 0.12 (0.38)
  Corona *radiata*                                  −0.14 (0.01); −0.13 (0.58); −0.14 (0.39)     0.17 (10^−3^); 0.15 (0.59); 0.18 (0.21)
  External capsule                                  −0.17 (10^−3^); −0.12 (0.68); −0.23 (0.23)   0.17 (10^−3^); 0.32 (0.37); 0.11 (0.40)
  Internal capsule (including thalamic radiation)   −0.12 (0.05); −0.17 (0.52); −0.09 (0.55)     0.14 (0.01); 0.21 (0.60); 0.11 (0.51)
  Superior/inferior fronto-occipital fasciculi      −0.15 (0.005); −0.05 (0.83); −0.21 (0.14)    0.14 (0.01); 0.22 (0.45); 0.11 (0.37)
  Superior longitudinal fasciculus                  −0.13 (0.02); −0.15 (0.51); −0.11 (0.51)     0.17 (0.002); 0.24 (0.39); 0.13 (0.38)
  Sagittal stratum                                  −0.08 (0.09); −0.32 (0.21); 0.06 (0.68)      0.12 (0.02); 0.34 (0.26); 0.02 (0.87)
  **REGIONAL HWM VOLUMES**                                                                       
  Subcortical                                       0.07 (0.10); 0.27 (0.10); 0.28 (0.10)        −0.14 (0.01); 0.08 (0.79); −0.25 (0.05)
  Periventricular                                   0.06 (0.25); 0.02 (0.95); 0.05 (0.75)        −0.06 (0.26); 0.15 (0.62); −0.17 (0.24)

The correlation between the *P-* and *L-selectin* expressions were not significant ρ~P~ (*p*), ρ~G~ (*p*), and ρ~E~ (*p*) = −0.08 (0.12), 0.16 (0.60), and −0.22 (0.16), respectively.

Discussion
==========

This study aimed to identify genes, located on chromosome 1q24, whose expression levels predicted brain atrophy in a population of well-characterized Mexican-Americans. Previous research in this population has demonstrated positive genetic relationships between *P-selectin* expressions and arterial hypertension (Goring et al., [@B16]) and between BP and pulse pressure and WM integrity (DeStefano et al., [@B10]; Rutherford et al., [@B38]). Here, we demonstrated that elevated mRNA expressions for *P-selectin* gene were prospectively associated with reduced cerebral integrity and this association was driven by shared genetic factors. In addition, we observed a positive phenotypic correlation between the *L-selectin* expression and cerebral FA values, which was driven by shared environmental factors. The blood samples used in this study were collected 16 years prior to the imaging assessments, minimizing the potential that these traits were influenced by stress associated with MR imaging (Tsankova et al., [@B42]). Overall, our finding supported the hypothesis that *P-selectin* is the likely to be involved in modulation of cerebral atrophy and that its mRNA expression level is a promising peripheral biomarker of cerebral health.

P-selectin is a cell adhesion protein, expressed by endothelial cells, that initiates adhesion to platelets and endothelial cells as the part of the inflammatory reaction. Elevated levels of soluble P-selectin protein in blood is a known risk factor for atherosclerosis (Csongradi et al., [@B9]), essential hypertension (Zee et al., [@B49]), cardiovascular disorders (Zakynthinos and Pappa, [@B48]), and stroke (Zee et al., [@B49]; Preston et al., [@B36]). Platelet derived *P-selectin* expression levels were shown to be positively correlated with blood levels of soluble P-selectin protein (Csongradi et al., [@B9]) and the diagnosis of the hypertension and atherosclerosis (Lee et al., [@B29]; Reiner et al., [@B37]; Nomura et al., [@B34]). Common SELP sequence variants, including *rs*2235302, *rs*6133, *rs*6136, and *rs*3917854, were demonstrated to explain a significant (5--13%) portion of individual variability in soluble P-selectin measured in plasma (Lee et al., [@B29]; Reiner et al., [@B37]). Our finding of significant negative correlation between *P-selectin* expression and cerebral integrity also replicates an observation in the Framingham heart study subjects where the blood level of P-selectin protein were negatively correlated with the brain volume (Preston et al., [@B36]). Further analyses, involving deep sequencing and functional variants will be necessary for the true identification of the specific polymorphisms that are associated with increased cerebral atrophy.

Significant phenotypic correlation was observed between *L-selectin* (*SELL*) expressions and FA of cerebral WM. The direction of the correlation indicated that increased *L-selectin* expression levels corresponded to higher FA values. The significance of the environmental correlation coefficient (ρ~E~) suggested that this relationship was driven by shared environmental factors. L-selectin protein has both adhesive and signaling functions and its physiological role is different from that of P-selectin (Shigeta et al., [@B40]). The L-selectin levels do not increased during essential hypertension (Sanada et al., [@B39]) and do not predict development of vascular inflammation during vascular encephalomyelitis (Doring et al., [@B11]). Experiments in lab animals demonstrate that *P-selectin* expression is significantly up-regulated in inflamed CNS microvessels but no significant change was observed for *L-selectin* expression (Doring et al., [@B11]). Instead, L-selectin levels were shown to be essential for leukocytes' recruitment into CNS in response to bacterial meningitis (Sulik et al., [@B41]), sepsis, and viral brain infections (Sulik et al., [@B41]) and were predictive of increased survival rates in patients with acute brain injury (Briassoulis et al., [@B7]). Additionally, L-selectin participates in the *in vitro* attachment of lymphocytes to WM with its ligand located on the actual myelin sheaths of CNS neurons (Huang et al., [@B19]). The shiverer mouse, which lacks compact myelin, has a greatly diminished density of L-selectin ligands (Huang et al., [@B19]). The positive relationship between the expression levels of *L-selectin* and FA values may, therefore, reflect upon the anti-inflammatory role of this gene in maintaining homeostasis of the cerebral WM.

This is the first study to empirically demonstrate the utility of lymphocyte-based *P-selectin* expression level measurements for a study of cerebral integrity phenotypes. Expression levels of *P-selectin* gene in the cerebral endothelial cells would be the ideal trait for this study. However, the impracticality of obtaining such measurements in large, genetically informative samples necessitates the use of a surrogate marker. On the other hand, *P-selectin* is highly expressed in human lymphocytes[^4^](#fn4){ref-type="fn"} and *P-selectin* protein is critically involved in the migration of lymphocytes into brain tissue during ischemic stroke injury (Marquardt et al., [@B31]; Yilmaz and Granger, [@B47]) and modulation of cerebral inflammation in multiple sclerosis (Piccio et al., [@B35]; Engelhardt, [@B13]). Additionally, other expression levels in lymphocytes have already been demonstrated to be good surrogates for gene expression in several neurological and psychiatric disease-relevant genes (Borovecki et al., [@B6]; Tsuang et al., [@B43]; Glahn et al., [@B15]). For instance, the lymphocyte-based expressions ranked higher than any of the behavioral or neurocognitive assessment measurement for marking the risk of major depressive disorder, suggesting that lymphocyte-based transcriptional profiles is an important marker for psychiatric disease risks (Glahn et al., [@B15]).

We observed no significant correlations between measurements of cerebral integrity and expression levels for two other, *ATP1B1* and *F5*, genes whose polymorphism were implicated as potential risk factors for essential hypertension BP in Caucasians (Kochunov et al., [@B23]). This could be due to ethnic differences as this study was focused on Mexican-Americans, a population with significant Native American admixture. Mexican-Americans are characterized by a higher rate of metabolic syndrome when compared with non-Hispanic whites in San Antonio (Mitchell et al., [@B33]). Elevated *P-selectin* expression levels are also observed in atherosclerosis, diabetes, obesity, and coronary artery disease (Zakynthinos and Pappa, [@B48]; Csongradi et al., [@B9]) and our findings may not be specific to hypertension, other than in the sense that hypertension is part of the metabolic syndrome. Therefore, the lack of finding of a significant correlation for *ATP1B1* and *F5* expression levels cannot be interpreted as conclusive evidence against the hypothesis that this relationship does not exists nor does it confirm the lack of the overall pleiotropic relationship.

Conclusion
==========

Our findings in a cohort of normally aging, community-dwelling, Mexican-Americans demonstrated that *P-selectin* is likely candidate, responsible for the bivariate QTL between measures of BP and cerebral integrity in the 1q24 region. Our analyses demonstrated that *P-selectin* expression levels explained 3--4% of the variability in the measurements of cerebral integrity. This is smaller than the predictive power of BP measurements on cerebral integrity (10--20%; Kochunov et al., [@B24]). However, it is similar to the prospective predictive power (∼5%) of the serum P-selectin levels on the intersubject variability in the carotid intima--media thickness measured 5 years later. Our findings also support the hypothesis of a direct genetic relationship between *P-selectin* expression and cerebral atrophy as proposed by two studies that demonstrated neurocognitive differences in the elderly carriers of 1087 allele of this gene (Mathew et al., [@B32]; Gunstad et al., [@B17]). However, allele-specific PCR validation will be necessary to name the specific genetic variants that are responsible for this association. Additional research is also needed to clarify if the lack of genetic association for the *ATP1B1* and *F5* genes, previously reported in Caucasians, may be due to ethnic differences in the Mexican-American population studied here.
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